GSK Expects Slower Uptake of RSV Vaccine Amid Record Sales for Shingles Shot

Despite being the world’s first approved vaccine against respiratory syncytial virus infection, GSK expects a slower initial rollout for Arexvy, CEO Emma Walmsley said during a second-quarter earnings briefing Wednesday, as reported by Reuters.